Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs

BACKGROUND: Patient-reported outcomes (PROs) are important when evaluating treatment benefits in rheumatoid arthritis (RA). We compared upadacitinib, an oral, selective JAK-1 inhibitor, with placebo to assess clinically meaningful improvements in PROs in patients with RA who have had inadequate resp...

Descripción completa

Detalles Bibliográficos
Autores principales: Strand, Vibeke, Schiff, Michael, Tundia, Namita, Friedman, Alan, Meerwein, Sebastian, Pangan, Aileen, Ganguli, Arijit, Fuldeore, Mahesh, Song, Yan, Pope, Janet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6889334/
https://www.ncbi.nlm.nih.gov/pubmed/31791386
http://dx.doi.org/10.1186/s13075-019-2059-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6889334/
https://www.ncbi.nlm.nih.gov/pubmed/31791386
http://dx.doi.org/10.1186/s13075-019-2059-8

Ejemplares similares